398 Views | 183 Downloads
Correspondence: Hyung-Min Kwon, MD, PhD, Department of Neurology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea, hmkwon@snu.ac.kr
Author Contributions: Drs Kwon and Chimowitz had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Kwon, Lynn, Turan, Derdeyn, Fiorella, Janis, Rumboldt, Chimowitz.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Kwon, Lynn.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Kwon, Lynn.
Obtained funding: Lynn, Turan, Chimowitz.
Administrative, technical, or material support: Kwon, Lynn, Derdeyn, Montgomery.
Study supervision: Kwon, Lynn, Turan, Janis, Chimowitz.
Role of the Funder/Sponsor: The funding organizations and sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
See publication for full list of disclosures.
This study was funded by a research grant (U01 NS058728) from the US Public Health Service National Institute of Neurological Disorders and Stroke (NINDS).
In addition, the following Clinical and Translational Science Awards, funded by the National Institutes of Health, provided local support for the evaluation of patients in the trial: Medical University of South Carolina (UL1RR029882), University of Florida (UL1RR029889), University of Cincinnati (UL1RR029890), and University of California, San Francisco (UL1RR024131).
Corporate Support: Stryker Neurovascular (formerly Boston Scientific Neurovascular) provided study devices and supplemental funding for third party device distribution, site monitoring, and study auditing.
This research was also supported by the Investigator-Sponsored Study Program of AstraZeneca, which donated rosuvastatin (Crestor) to study patients.
Vendors: INTERVENT provided the lifestyle modification program to the study at a discounted rate.
The Regulatory and Clinical Research Institute (RCRI) (Minneapolis, MN) provided assistance in designing the site monitoring processes and perform the site monitoring visits.
The VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center (Albuquerque, NM) handled the procurement, labeling, distribution, and inventory management of the study devices and rosuvastatin.
Walgreens pharmacies provided study medications except rosuvastatin to patients at a discounted price (paid for by the study).
© 2018 American Medical Association. All Rights Reserved.